Margarida Maia, PhD,  science writer—

The rate of new cases, or incidence of cystic fibrosis (CF) is gradually and annually decreasing in the U.S. and Canada alike — and has been for nearly a quarter of century — a new study found. From 1995 to 2019, CF incidence has dropped at a rate of…

Most people with cystic fibrosis (CF) have fungi in their airways, but the fungi may come and go in waves of activity, a Spanish study suggests. The study, “Fungal microbiota dynamics and its geographical, age and gender variability in patients with cystic fibrosis,” was published in Clinical Microbiology…

Treatment with Trikafta continues to be safe and well-tolerated, benefiting people with cystic fibrosis (CF) ages 12 and up who have been on treatment for almost three years. But benefits may also extend to children as young as 2. That’s according to data that will be shared at…

A Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, Adaptive Phage’s experimental cocktail of bacteriophages, or viruses that selectively target and kill bacteria, is now recruiting cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections. The study (NCT05453578) seeks to enroll up to 72 adults with CF who test positive…

Trikafta (elexacaftor/tezacaftor/ivacaftor) may bring health-related quality of life benefits to people with cystic fibrosis (CF) that go beyond those already reported for breathing, a study found. This expectation stems from a new look by an international team of researchers into data from the two Phase 3 clinical trials that…

The bacteria that causes chronic rhinosinusitis — swelling of the nasal cavity and sinuses — in people with cystic fibrosis (CF) are also those that often seed infections in their lungs, which means preventing or treating sinus disease may help better manage the symptoms of CF, a study suggests.

Young patients with cystic fibrosis (CF) who have a lung infection caused by Staphylococcus bacteria may have worse lung function and more exacerbations than those who are infected with Pseudomonas bacteria, a Brazilian study has found. The study, “Lower airway microbiota and decreasing lung function in young Brazilian…

A type of ring-shaped molecule called a macrocycle can help CFTR — the faulty protein in cystic fibrosis (CF) — go to the cell’s membrane, where it exerts its action, and work better in lab-grown cells carrying the most common CF-causing mutation, a study showed. These benefits were associated…

Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may ease acid reflux and symptoms of nasal and sinus cavity infection in cystic fibrosis (CF) patients with advanced lung disease, a U.K.-based study found. The study, “Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and…

Taking so-called CFTR modulators — medications to correct the disease-causing faulty CFTR protein in cystic fibrosis (CF) — may significantly reduce a patient’s risk of severe COVID-19, according to a study by an international team of researchers. In fact, non-lung transplant CF patients in the U.S. and the U.K. using…